Celldex Therapeutics Quarterly Income Statement
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Celldex Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Celldex Therapeutics generated $22,000 in revenue, down 97.0% from the same quarter a year earlier. Celldex Therapeutics reported a net loss of $73.5 million, compared with a loss of $56.6 million a year earlier. Operating margin was -366468.2%.
Diluted earnings per share came in at -$0.94.
Summary generated from market data by MetaCap's automated system. Methodology
Celldex Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.00K | 15.00K | 121.00K | 0 | 730.00K | 695.00K | 1.18M | 3.19M | 2.50M | 156.00K | 4.13M | 1.52M |
| Revenue growth (YoY) | -96.99% | -97.84% | -89.70% | -100.00% | -70.78% | +345.51% | -71.56% | +110.35% | +832.09% | -83.87% | +156.11% | +272.73% |
| Research & Development | 67.54M | 73.00M | 75.33M | 62.93M | 54.20M | 52.61M | 46.94M | 45.26M | 39.69M | 31.66M | 30.43M | 34.53M |
| Operating Income | -80.62M | -84.44M | -87.15M | -73.62M | -63.86M | -62.74M | -56.03M | -52.13M | -46.32M | -40.61M | -47.63M | -41.24M |
| Net Income | -73.50M | -78.69M | -81.32M | -67.04M | -56.60M | -53.80M | -47.09M | -42.12M | -35.84M | -32.81M | -43.31M | -38.26M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.94 | -1.18 | -1.23 | -1.01 | -0.85 | -0.81 | -0.71 | -0.64 | -0.54 | -0.56 | -0.84 | -0.81 |
| EPS (Diluted) | -0.94 | -1.18 | -1.23 | -1.01 | -0.85 | -0.81 | -0.71 | -0.64 | -0.54 | -0.56 | -0.84 | -0.81 |
| Shares Outstanding (Basic) | 77.84M | 66.57M | — | 66.42K | 66.39M | 66.38M | — | 66.29K | 66.02K | 58.87K | — | 47.26K |
| Shares Outstanding (Diluted) | 77.84M | 66.57M | — | 66.42K | 66.39M | 66.38M | — | 66.29K | 66.02K | 58.87K | — | 47.26K |
| EBITDA | -79.72M | -83.58M | -86.34M | -72.79M | -62.98M | -61.87M | -55.21M | -51.34M | -45.52M | -39.83M | -46.87M | -40.47M |
| Operating Margin | -366468.18% | -562900.00% | -72027.27% | — | -8747.53% | -9027.19% | -4768.26% | -1633.53% | -1854.16% | -26030.77% | -1152.92% | -2718.46% |
| Net Margin | -334104.55% | -524566.67% | -67204.13% | — | -7753.42% | -7740.43% | -4007.83% | -1319.99% | -1434.83% | -21030.77% | -1048.32% | -2522.08% |
This table shows 12 quarterly periods of Celldex Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow CLDX's reporting calendar. What is a income statement?